February 20, 2024 12:20 PM ESTUpdated 12:57 PM
Manufacturing

Re­silience al­lo­cates $225M to ex­pand man­u­fac­tur­ing ca­pac­i­ty in Cincin­nati

Ayisha Sharma

News Reporter

Na­tion­al Re­silience is work­ing to ex­pand its clin­i­cal and com­mer­cial drug man­u­fac­tur­ing ca­pa­bil­i­ties to pro­vide more than 200 mil­lion units to its clients by 2025 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times